CytoSorbents Reports Third Quarter 2025 Revenue of $9.5 Million

Reuters

11/14

CytoSorbents Reports Third Quarter 2025 Revenue of $9.5 Million

CytoSorbents Corporation reported third quarter 2025 revenue of $9.5 million, representing a 10% increase year-over-year. The company amended its credit agreement with Avenue Capital Group, gaining an additional $2.5 million in cash and extending the interest-only period through December 31, 2026, with a further $2.5 million available and a possible extension to June 30, 2027, contingent on DrugSorb-ATR FDA marketing approval. Proforma cash, cash equivalents, and restricted cash totaled $11.6 million as of September 30, 2025, assuming the additional term loan capital had been drawn, with total proforma debt at $17.5 million. CytoSorbents also implemented a Workforce and Cost Reduction Program, aiming to accelerate its path to cash-flow breakeven by the first quarter of 2026. The company submitted a DrugSorb-ATR De Novo pre-submission package to the FDA, with a meeting expected in late 2025 or early 2026 and a regulatory decision anticipated by mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000929638-25-004243), on November 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583051272"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583051272\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583051272?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583051272","market":"us","top_or_hot":-1,"title":"CytoSorbents Reports Third Quarter 2025 Revenue of $9.5 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CytoSorbents Reports Third Quarter 2025 Revenue of $9.5 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CytoSorbents Corporation reported third quarter 2025 revenue of $9.5 million, representing a 10% increase year-over-year. The company amended its credit agreement with Avenue Capital Group, gaining an additional $2.5 million in cash and extending the interest-only period through December 31, 2026, with a further $2.5 million available and a possible extension to June 30, 2027, contingent on DrugSorb-ATR FDA marketing approval. Proforma cash, cash equivalents, and restricted cash totaled $11.6 million as of September 30, 2025, assuming the additional term loan capital had been drawn, with total proforma debt at $17.5 million. CytoSorbents also implemented a Workforce and Cost Reduction Program, aiming to accelerate its path to cash-flow breakeven by the first quarter of 2026. The company submitted a DrugSorb-ATR De Novo pre-submission package to the FDA, with a meeting expected in late 2025 or early 2026 and a regulatory decision anticipated by mid-2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000929638-25-004243), on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoSorbents Reports Third Quarter 2025 Revenue of $9.5 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoSorbents Reports Third Quarter 2025 Revenue of $9.5 Million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-14 05:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CytoSorbents Reports Third Quarter 2025 Revenue of $9.5 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CytoSorbents Corporation reported third quarter 2025 revenue of $9.5 million, representing a 10% increase year-over-year. The company amended its credit agreement with Avenue Capital Group, gaining an additional $2.5 million in cash and extending the interest-only period through December 31, 2026, with a further $2.5 million available and a possible extension to June 30, 2027, contingent on DrugSorb-ATR FDA marketing approval. Proforma cash, cash equivalents, and restricted cash totaled $11.6 million as of September 30, 2025, assuming the additional term loan capital had been drawn, with total proforma debt at $17.5 million. CytoSorbents also implemented a Workforce and Cost Reduction Program, aiming to accelerate its path to cash-flow breakeven by the first quarter of 2026. The company submitted a DrugSorb-ATR De Novo pre-submission package to the FDA, with a meeting expected in late 2025 or early 2026 and a regulatory decision anticipated by mid-2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000929638-25-004243), on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTSO","symbol_name":"Cytosorbents Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL5RY1GY:1","article_id":"2583051272","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583051272","pubTimestamp":1763069733,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CytoSorbents Corporation reported third quarter 2025 revenue of $9.5 million, representing a 10% increase year-over-year. The company amended its credit agreement with Avenue Capital Group, gaining an additional $2.5 million in cash and extending the interest-only period through December 31, 2026, with a further $2.5 million available and a possible extension to June 30, 2027, contingent on DrugSorb-ATR FDA marketing approval. Proforma cash, cash equivalents, and restricted cash totaled $11.6 million as of September 30, 2025, assuming the additional term loan capital had been drawn, with total proforma debt at $17.5 million. CytoSorbents also implemented a Workforce and Cost Reduction Program, aiming to accelerate its path to cash-flow breakeven by the first quarter of 2026. The company submitted a DrugSorb-ATR De Novo pre-submission package to the FDA, with a meeting expected in late 2025 or early 2026 and a regulatory decision anticipated by mid-2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTSO":"Cytosorbents Corporation","BK4082":"医疗保健设备"},"translate_title":"CytoSorbents报告2025年第三季度收入为950万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTSO":0.9},"content_text":"CytoSorbents Reports Third Quarter 2025 Revenue of $9.5 Million\n    \n\n        CytoSorbents Corporation reported third quarter 2025 revenue of $9.5 million, representing a 10% increase year-over-year. The company amended its credit agreement with Avenue Capital Group, gaining an additional $2.5 million in cash and extending the interest-only period through December 31, 2026, with a further $2.5 million available and a possible extension to June 30, 2027, contingent on DrugSorb-ATR FDA marketing approval. Proforma cash, cash equivalents, and restricted cash totaled $11.6 million as of September 30, 2025, assuming the additional term loan capital had been drawn, with total proforma debt at $17.5 million. CytoSorbents also implemented a Workforce and Cost Reduction Program, aiming to accelerate its path to cash-flow breakeven by the first quarter of 2026. The company submitted a DrugSorb-ATR De Novo pre-submission package to the FDA, with a meeting expected in late 2025 or early 2026 and a regulatory decision anticipated by mid-2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000929638-25-004243), on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}